118
A
A
P
P
Ê
Ê
N
N
D
D
I
I
C
C
E
E
H
H
Abastecimento
GSK/Supplier
GSK comments Supplier comments Action Plan:
Area
Jan – Nov 2005
Comments/Recommendation Comments/Recommendation
0 = Poor
10 = Excellent
Capacity - Comply with Annual Volume Requirements negotiated
with
GSK.
8
Molds from GSK with limited capacity.
Supplier had not achieve optimal production
conditions in the area.
Esta situación fue temporal debido a la
corrección de moldes con problemas
de capacidad, la capacidad actual
cubre las necesidades del cliente a
partir de mediados de Octubre
Capacidad regularizada para cubrir las
neceisdades del cliente en Octobre.
Reengineering molds, Intra & Mama
- when achieve 70%, need to
increase capacity.
Capacity - Ability to ramp up capacity to 100% of monthly volume
requirement. Emergencies lead time to be negotiated with supplier
and GSK
1
Molds from GSK with limited capacity.
Supplier had not achieve optimal production
conditions in the area.
Capacity - Meet GSK's economic lots.
6
Supplier have been delivering goods below
the economical lots agreed.
Si estamos cumpliendo porque
evaluación es menor a 10
Capacity - Meet
GSK's
package quantities per shipping case.
5
Supplier is not achieving GSK shipping case
specifications.
La caja actual de entrega optimiza flete
y las propuestas NO han sido
aceptadas por GSK al efectar
incremento en costos
GSK tiene pendiente de aprovechar el
tipo de caja actual para NO afectar su
capacidad de almacenaje
Delivery performance - KPI 5.6 in 95%
6
Average KPI June - 69%. Supplier have been
delivering goods below the minimum
percentage of 90%.
En Sep., Oct., Nov. hemos obtenido el
100 % sin embargo Compras NO ha
corregido evaluación
Compras deberá corregir evalución
solicitada por Supplier debido a que
las entregas se entorpecierón por
negociación de precios y cambio de
Razón Social
Delivery performance - in case of supply risk, supplier must notify
to GSK any quality issue that will afect supplyment (Ex. lack of
material, strikes, equipments, ...)
8
Some non expected issues informed by
Supplier. Inventory information
Delivery performance - freight transportation with security
container and optimized quantities.
10
No issue.
Work with GSK to implement transport
loops
Plant facility - Sufficient equipment at multiple sites to support a
portfolio of projects at all scales. Able to support a wide range of
physical handling demands.
10
Supplier has been able to extend additional
projects.
Inventory - Some pre-cursor stocks, supplier owned, held to
ensure fast start in response to unscheduled demand, or when
manufacturing issues cause material shortfall.
4
Supplier could not built the safety stock to
GSK.
Supplier ha manejado inventarios con
15 días de la demanda del siguiente
mes, esto NO ocurrió en Ago., y Sep.
Por corrección de moldes por
capacidad y verticalidad
Supplier continua planeando y
produciendo producto para tener 15
días de inventario
Safety - EHS policy. H & S of employees and “neighbours” top
priority. Integral part of company culture with regular awareness
sessions used. Performance in the area monitored closely with
improvement plans identified. State of art working environment.
9
Supply Chain Management - Comprehensive Supply Chain
Management processes in place, including active supplier
management, through all aspects of manufacturing, to delivery to
GSK. Performance is regularly measured, and improvements
made. Focussed, proactive approach with supplier approval
process in place, compliance audits carried out for all key
materials. Secure supply established on key input materials with
contingency plans in place.
7
Supply Contingency - Contingency plan agreed with supplier in
case of shortage of materials, machine break-down, strikes,etc
7
Supplier is working to develop alternative
sources for resin specifications.
Develop alternative sources for resin
in South America or Asia.
Supplier Contingency - Process validation/qualification complete at
supplier's sites. Contingency plans in place to cover against
complete site disablement.
5
No validation when starting the process
operation. There is no other facility approved
to supply GSK.
Response to New Enquiry’s - Able to meet or better GSK generic
targets for the evaluation of new projects and lead-times for the
manufacture of initial supplies.
4
Delays on implementation of new projects and
delay on start-up of new projects.
Followup between leader GSK /
Supplier Team
Lead Time - 'Visible' lead-times and effective two-way
communication allows management of available capacity.
8
Supplier sometime has given
wrong/unrealistic lead-times.
Open discussions between GSK and
Supplier to define timings and risks,
also well define commitment of the two
parties